Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Indication: Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia (ALPINE) - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Indication: Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia (ALPINE)

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia (ALPINE)

New Indication: Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia (ALPINE)
Study:
  • Phase III, randomized, open-label study
  • Relapsed or refractory CLL/SLL
  • Zanubritinib (n=327) vs. İbrutinib (n=325)
Efficacy:
  • 24 mos PFS: 78.4% vs. 65.9%
  • mPFS: NR vs. 34.2 mos, HR:0.65, p=0.002
  • ORR: 86.2% vs 75.7%
Safety:
  • Grade≥3 AEs: neutropenia (16% vs. 13.9%), hypertension (14.8% vs. 11.1%), Covid-19 related pneumonia (7.1% vs. 4.0%)

N Engl J Med 2023; 388:319-332

Brown R.J et al. ¨Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia¨

http://doi.org/0.1056/NEJMoa2211582

Reviewed by Elvin CHALABİYEV, MD on FEB 24, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More